March 17 (Reuters) - Lantheus Holdings LNTH.O said on Tuesday that the U.S. Food and Drug Administration has extended its review of the company's diagnostic imaging kit by three months.
The agency will now give its decision on the imaging kit's approval by June 29.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Shailesh Kuber)
((Kamal.Choudhury@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.